Developing nanomedicines to target prostate tumours using bispecific antibodies and a comparative oncology approach.

Prostate cancer is the most common cancer in men over 50 and second most frequent cause of cancer deaths in Western society. This project aims to enhance uptake of the prostate cancer drug docetaxel into prostate tumours by exploiting immune-targeting techniques using bispecific antibodies. We will use a comparative oncology approach to test the nanomedicine in canine patients that have been diagnosed with prostate cancer – these patients exhibit cancer that is representative of the human disease. This strategy addresses a number of important problems associated with prostate cancer therapies, most notably the reduction of side-affects associated with indiscriminate toxicity of docetaxel. In addition, use of antigen interactions to chelate targeting antibodies to liposomal formulations alleviates the need for complex and often unstable chemistries. This research will ultimately provide both a fundamental understanding of nanomedicine-based therapeutics, as well as advancement towards clinical translation of the therapy. A collaboration with A/Prof Steve Mahler (AIBN) and Prof Andrew Boyd (QIMR).

Project members

Associate Professor Kris Thurecht

Group Leader - Principal Research Fellow
Centre for Advanced Imaging

Professor Pamela Russell

Honorary Professor

Dr Christopher Howard

Research Fellow
Centre for Advanced Imaging